Similarly, we do not observe an extension of survival when combining the RAS(ON) G12C-selective inhibitor RMC-4998 with anti-PD-1 in 3LL-ΔNRAS tumours, an immune-excluded model representative of lung tumours that are intrinsically resistant to ICB. This evidence concerns the gene PDCD1 and neoplasm.